JPS6129330B2 - - Google Patents

Info

Publication number
JPS6129330B2
JPS6129330B2 JP52158099A JP15809977A JPS6129330B2 JP S6129330 B2 JPS6129330 B2 JP S6129330B2 JP 52158099 A JP52158099 A JP 52158099A JP 15809977 A JP15809977 A JP 15809977A JP S6129330 B2 JPS6129330 B2 JP S6129330B2
Authority
JP
Japan
Prior art keywords
group
lower alkyl
alkyl group
formula
yloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP52158099A
Other languages
Japanese (ja)
Other versions
JPS5492926A (en
Inventor
Atsushi Matsumoto
Atsuo Kojima
Isao Oohata
Noboru Sato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Priority to JP15809977A priority Critical patent/JPS5492926A/en
Priority to GB8124879A priority patent/GB2086377B/en
Priority to GB7848658A priority patent/GB2011888B/en
Priority to CA318,098A priority patent/CA1110248A/en
Priority to DE19782854595 priority patent/DE2854595A1/en
Priority to FR7836263A priority patent/FR2413382A1/en
Priority to NL7812574A priority patent/NL7812574A/en
Priority to BE192584A priority patent/BE873102A/en
Priority to ES476458A priority patent/ES476458A1/en
Priority to SE7813355A priority patent/SE7813355L/en
Priority to NO784394A priority patent/NO784394L/en
Priority to DK584978A priority patent/DK584978A/en
Priority to IT7869973A priority patent/IT7869973A0/en
Priority to AU43017/78A priority patent/AU4301778A/en
Priority to AT0935778A priority patent/AT367738B/en
Priority to ES481505A priority patent/ES481505A1/en
Priority to ES481504A priority patent/ES481504A1/en
Publication of JPS5492926A publication Critical patent/JPS5492926A/en
Priority to CA356,441A priority patent/CA1110246A/en
Priority to FR8016962A priority patent/FR2457863A1/en
Priority to NO820355A priority patent/NO820355L/en
Publication of JPS6129330B2 publication Critical patent/JPS6129330B2/ja
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明は式()で示される新規なアミノフエ
ニルエーテル化合物およびその薬理的に許容され
る塩に関する。 [式中、Rは水素原子を、R1は水素原子または低
級アルキル基を、R2は低級アルキル基で置換さ
れていてもよいシクロペンチル基もしくはシクロ
ヘキシル基、炭素数1〜20個のアルキル基、フエ
ニル基、またはベンジル基を、R3は水素原子、
低級アルキル基、低級アルキル基で置換されてい
てもよいシクロペンチル基もしくはシクロヘキシ
ル基、フエニル基、またはベンジル基を、R4
水素原子、低級アルキル基、アラルキル基、また
は低級アルコキシカルボニル基を、R5は水素原
子、低級アルキル基、式一COR6(式中R6は低級
アルキル基、シクロヘキシル基、アリール基、ア
ラルキル基、アラルケニル基、低級アルキル基で
置換されていてもよいアミノ基、または有橋炭化
水素基を表わす) で示される基を表わす。但し、前記R2とR3は隣
接炭素原子と一体となつて低級アルキル基で置換
されてもよいシクロヘキサン環を形成してもよ
く、また前記R4とR5は隣接窒素原子と一体とな
つてピロリジン環、ピペリジン環またはモルホリ
ン環を形成してもよい。] 式()で示されるアミノフエニルエーテル化
合物において
The present invention relates to a novel aminophenyl ether compound represented by formula () and a pharmaceutically acceptable salt thereof. [In the formula, R is a hydrogen atom, R 1 is a hydrogen atom or a lower alkyl group, R 2 is a cyclopentyl group or cyclohexyl group that may be substituted with a lower alkyl group, an alkyl group having 1 to 20 carbon atoms, phenyl group or benzyl group, R 3 is hydrogen atom,
A lower alkyl group, a cyclopentyl group or cyclohexyl group optionally substituted with a lower alkyl group, a phenyl group, or a benzyl group, R 4 is a hydrogen atom, a lower alkyl group, an aralkyl group, or a lower alkoxycarbonyl group, R 5 is a hydrogen atom, a lower alkyl group, a COR 6 (in the formula, R 6 is a lower alkyl group, a cyclohexyl group, an aryl group, an aralkyl group, an aralkenyl group, an amino group optionally substituted with a lower alkyl group, or a bridged (represents a hydrocarbon group) However, R 2 and R 3 may be combined with adjacent carbon atoms to form a cyclohexane ring which may be substituted with a lower alkyl group, and R 4 and R 5 may be combined with adjacent nitrogen atoms. may be used to form a pyrrolidine ring, piperidine ring or morpholine ring. ] In the aminophenyl ether compound represented by formula ()

【式】で示される部分構造が 二置換シクロヘキサン環を有する場合には、シス
またはトランス立体異性体が存在する。 ここに「ハロゲン原子」とは塩素原子、臭素原
子、フツ素原子等を意味し、「低級アルキル基」
とはメチル基、エチル基、イソプロピル基、ブチ
ル基、イソペンチル基、ヘキシル基等の炭素数1
〜6個の直鎖または分枝状のアルキル基を、「低
級アルコキシ基」とはメトキシ基、エトキシ基、
ブトキシ基等の炭素数1〜6個のアルコキシ基を
意味する。また「アリール基」としては、たとえ
ばフエニル基、ナフチル基等が、「アラルキル
基」としては、たとえばベンジル基、フエネチル
基、フエニルプロピル基等が、「低級アルコキシ
カルボニル基」としては、たとえばメトキシカル
ボニル基、エトキシカルボニル基、ブトキシカル
ボニル基等が、「アラルケニル基」としては、た
とえばスチリル基、シンナミル基等が挙げられ
る。「置換アミノ基」としては、メチルアミノ
基、エチルアミノ基、イソブチルアミノ基等の低
級アルキルアミノ基、ジメチルアミノ基、ジエチ
ルアミノ基、ジブチルアミノ基等のジ低級アルキ
ルアミノ基等が、「有橋炭化水素基」としては、
たとえばビシクロノニル基、ビシクロデシル基、
アダマンチル基、ピナニル基、ボルニル基等が挙
げられる。 本発明化合物()の薬理的に許容される塩と
しては、塩酸、臭化水素酸、リン酸等の無機酸と
の酸付加塩、ギ酸、乳酸、シユウ酸、コハク酸、
フマル酸、安息香酸、ベンゼンスルホン酸等の有
機酸との酸付加塩、およびヨウ化メチル等のハロ
ゲン化アルキルとの第4アンモニウム塩等が挙げ
られる。 本発明化合物は脂質低下作用、特にすぐれたコ
レステロールおよびトリグリセライド低下作用を
有しており、動脈硬化症およそれに起因する心臓
血管系等の疾患の予防、治療に有効である。動脈
硬化症は血液中にコレステロール、トリグリセラ
イド等の脂質が過剰になることが一因となつてお
り、従来脂質低下剤としてp−クロロフエノキシ
イソ酪酸エチルエステル(クロフイブレート)が
汎用されているが、より効力が強く、副作用の少
い薬剤の開発が望まれている。本発明者らは鋭意
研究した結果、前記式()で示される化合物が
すぐれたコレステロール並びにトリグリセライド
低下作用および血液中の高比重リポ蛋白
(HDL)の選択的増加作用を有することを見いだ
し本発明を完成にするに至つた。HDLは動脈硬
化症時にはその量が正常時より減少しているこ
と、また動脈壁中へのコレステロールの過剰蓄積
を阻止することや動脈壁からのコレステロールの
流出を促進することが知られており、HDLの増
加は動脈硬化症の治療、予防に有効である。 本発明化合物の効果の確認は、生後3週間目の
スプラグドウリー(Sprague−Dawley)の雄性
ラツトにコレステロール1.5%と胆汁酸0.5%含有
食蝕を7日間与え、最後の4日間、メチルセルロ
ーズ0.25%水溶液に懸濁させた本発明化合物を1
日1回経口ゾンデによつて投与し、一夜絶食後、
エーテル麻酔下採血し、血清の総コレステロール
およびHDLの量を測定することにより行なわれ
る。コレステロールの測定は“Schettler、G&
Nussel;Arbeitsmed.Sozialmed.
Praventivmed.10、25(1975)”に記載されてい
る方法で、またHDLの測定は“T.T.Ishikawa
etal;Lipids、11628(1976)”に記載されている
方法で行うことができる。この実験により本発明
化合物はラツトにおいて10〜25mg/Kg(1日量)
で著しく効果があることが判明した。 本発明化合物は、一般に使用されている製剤用
添加剤を用いて散剤、顆粒剤、錠剤、カプセル
剤、注射剤等の製剤にすることができる。投与方
法は経口で行うのが好ましく、投与量は患者の症
状、年令等によつて異なるが、経口投与の場合、
通常成人1日1〜100mg/Kg、好ましくは5〜25
mg/Kg程度である。 本発明化合物()は種々の方法によつて製造
することが可能であるが、たとえば次の反応式で
示される第1〜5方法で製造することができる。 第1方法 本発明化合物()のうち式() (式中R、R1、R2およびR3は前記と同じ意味を表
わす。) で示される化合物は式() (式中、R1′は水素原子、低級アルキル基または低
級アルケニル基を、R2′は炭素数が1〜20個のア
ルキル基もしくはアルケニル基、フエニル基、ベ
ンジル基、または低級アルキル基もしは低級アル
ケニル基でそれぞれ置換されていてもよいシクロ
ペンチル基、シクロペンテニル基、シクロヘキシ
ル基またはシクロヘキセニル基を、R3′は水素原
子、低級アルキル基、低級アルケニル基、フエニ
ル基、ベンジル基、または低級アルキル基もしく
は低級アルケニル基でそれぞれ置換されていても
よいシクロペンチル基、シクロペンテニル基、シ
クロヘキシル基またはシクロヘキセニル基を表わ
す。但し、前記R2′とR3′とは隣接炭素原子と一体
となつて低級アルキル基もしくは低級アルケニル
基でそれぞれ置換されていてもよいシクロヘキサ
ン環またはシクロヘキセン環を形成してもよ
い。) で示されるアルコール化合物と式() (式中Xはハロゲン原子を表わし、Rは前記と同
じ意味を表わす。) で示されるp−ハロゲノニトロベンゼンとを強塩
基の存在下に反応させ、ついで生成物を還元する
ことによつて得ることができる。 この反応は有機溶媒、たとえばベンゼン、トル
エン、キシレン、ジメチルホルムアミド、ジメチ
ルスルホキシド、テトラヒドロフラン、ジオキサ
ン等、またはそれらの混合溶媒中加熱下で行なう
のが好ましい。強塩基としては、たとえばナトリ
ウム、カリウム、リチウム、ナトリウムハイドラ
イド、カリウムハイドライド、リチウムハイドラ
イド等が好適であり、アルコール化合物()と
これらの強塩基とをあらかじめ反応させておいて
からp−ハロゲノニトロベンゼン()と反応さ
せるのが好ましい。 還元は通常の方法、たとえば水素雰囲気中でラ
ネーニツケル、白金、パラジウム等を触媒として
用いる接触還元により、または酸性条件下で鉄、
亜鉛、スズ等の金属を使用しての還元等により行
なうことができる。この接触還元はニトロ基の還
元だけでなく基
When the partial structure represented by the formula has a disubstituted cyclohexane ring, cis or trans stereoisomers exist. Here, "halogen atom" means chlorine atom, bromine atom, fluorine atom, etc., and "lower alkyl group"
means 1 carbon number such as methyl group, ethyl group, isopropyl group, butyl group, isopentyl group, hexyl group, etc.
~6 straight chain or branched alkyl groups, "lower alkoxy group" refers to methoxy group, ethoxy group,
It means an alkoxy group having 1 to 6 carbon atoms such as a butoxy group. Further, examples of the "aryl group" include phenyl group, naphthyl group, etc., examples of the "aralkyl group" include benzyl group, phenethyl group, phenylpropyl group, etc., and examples of the "lower alkoxycarbonyl group" include methoxycarbonyl group. Examples of the "aralkenyl group" include a styryl group, a cinnamyl group, and the like. Examples of the "substituted amino group" include lower alkylamino groups such as methylamino, ethylamino, and isobutylamino groups; di-lower alkylamino groups such as dimethylamino, diethylamino, and dibutylamino; As "hydrogen group",
For example, bicyclononyl group, bicyclodecyl group,
Examples include an adamantyl group, a pinanyl group, and a bornyl group. Pharmaceutically acceptable salts of the compound () of the present invention include acid addition salts with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, formic acid, lactic acid, oxalic acid, succinic acid,
Examples include acid addition salts with organic acids such as fumaric acid, benzoic acid and benzenesulfonic acid, and quaternary ammonium salts with alkyl halides such as methyl iodide. The compounds of the present invention have lipid-lowering effects, particularly excellent cholesterol- and triglyceride-lowering effects, and are effective in preventing and treating diseases of the cardiovascular system and the like caused by arteriosclerosis. Arteriosclerosis is caused by excess lipids such as cholesterol and triglycerides in the blood, and p-chlorophenoxyisobutyric acid ethyl ester (clofibrate) has been commonly used as a lipid-lowering agent. However, there is a desire to develop a drug that is more effective and has fewer side effects. As a result of extensive research, the present inventors discovered that the compound represented by the above formula () has an excellent effect of lowering cholesterol and triglyceride, and an effect of selectively increasing high-density lipoprotein (HDL) in the blood. I was able to complete it. It is known that the amount of HDL decreases during arteriosclerosis compared to normal levels, and that it prevents excessive accumulation of cholesterol in the arterial walls and promotes the flow of cholesterol from the arterial walls. Increase in HDL is effective in treating and preventing arteriosclerosis. To confirm the effectiveness of the compound of the present invention, male Sprague-Dawley rats, 3 weeks old, were fed a diet containing 1.5% cholesterol and 0.5% bile acid for 7 days, and for the last 4 days, methylcellulose 0.25 The compound of the present invention suspended in an aqueous solution of 1%
Administered once daily by oral probe, after overnight fasting,
It is performed by collecting blood under ether anesthesia and measuring the amount of serum total cholesterol and HDL. Cholesterol measurement is performed by “Schettler, G.
Nussel;Arbeitsmed.Sozialmed.
Praventivmed.10, 25 (1975)”, and HDL was measured using the method described in “TTIshikawa
etal; Lipids, 11628 (1976). In this experiment, the compound of the present invention was administered to rats at a dose of 10 to 25 mg/Kg (daily dose).
was found to be significantly effective. The compound of the present invention can be made into formulations such as powders, granules, tablets, capsules, and injections using commonly used formulation additives. The administration method is preferably oral, and the dosage varies depending on the patient's symptoms, age, etc., but in the case of oral administration,
Usually 1-100mg/Kg per day for adults, preferably 5-25
It is about mg/Kg. The compound () of the present invention can be produced by various methods, and for example, it can be produced by methods 1 to 5 shown in the following reaction formula. First method Formula () of the compound () of the present invention (In the formula, R, R 1 , R 2 and R 3 have the same meanings as above.) The compound represented by the formula () (In the formula, R 1 ' is a hydrogen atom, a lower alkyl group, or a lower alkenyl group, and R 2 ' is an alkyl group or alkenyl group having 1 to 20 carbon atoms, a phenyl group, a benzyl group, or a lower alkyl group or A cyclopentyl group, a cyclopentenyl group, a cyclohexyl group, or a cyclohexenyl group, each of which may be substituted with a lower alkenyl group, and R 3 ' is a hydrogen atom, a lower alkyl group, a lower alkenyl group, a phenyl group, a benzyl group, or a lower alkyl group. represents a cyclopentyl group, a cyclopentenyl group, a cyclohexyl group, or a cyclohexenyl group, each of which may be substituted with a group or a lower alkenyl group.However, R 2 ' and R 3 ' together with the adjacent carbon atoms represent a lower A cyclohexane ring or a cyclohexene ring which may be substituted with an alkyl group or a lower alkenyl group, respectively, may be formed.) and an alcohol compound represented by the formula () (In the formula, X represents a halogen atom, and R represents the same meaning as above.) By reacting p-halogenonitrobenzene represented by the formula in the presence of a strong base, and then reducing the product. I can do it. This reaction is preferably carried out in an organic solvent such as benzene, toluene, xylene, dimethylformamide, dimethylsulfoxide, tetrahydrofuran, dioxane, etc., or a mixed solvent thereof under heating. As the strong base, for example, sodium, potassium, lithium, sodium hydride, potassium hydride, lithium hydride, etc. are suitable, and the alcohol compound (2) is reacted with these strong bases before p-halogenonitrobenzene (2). It is preferable to react with Reduction can be carried out by conventional methods, for example by catalytic reduction using Raney nickel, platinum, palladium, etc. as catalysts in a hydrogen atmosphere, or by reducing iron, iron, etc. under acidic conditions.
This can be carried out by reduction using a metal such as zinc or tin. This catalytic reduction not only reduces nitro groups but also

【式】に存する二重結合の 水素添加も可能である。 第2方法 本発明化合物のうち式() (式中R、R1、R2、R3およびR6は前記と同じ意味
を表わす。) で示される化合物は第1方法で得られる化合物 と式() R6−COOH () (式中R6は前記と同じ意味を表わす。) で示されるカルボン酸またはその反応性誘導体と
を反応させることによつて得ることができる。 この反応は有機溶媒、たとえばベンゼン、トル
エン、キシレン、ジメチルホルムアミド、ジメチ
ルスルホキシド、テトラヒドロフラン、ピリジ
ン、ジオキサン等、またはそれらの混合溶媒中冷
却下乃至室温下で行なうのが好ましい。前記カル
ボン酸()を用いるときは、ジシクロヘキシル
カルボジイミドの如き縮合剤の存在下で反応を行
なうのがよい。カルボン酸()の反応性誘導体
としては、酸クロリド、酸ブロミド等の酸ハライ
ド、ベンジルリン酸、アルキル炭酸、ピバリン酸
等との混酸無水物、p−ニトロフエニルエステ
ル、チオフエニルエステル等の活性エステル、酸
無水物等が挙げられる。 第3方法 本発明化合物のうち式() または式() (式中R7は低級アルキル基、アリール基、アラル
キル基または低級アルコキシカルボニル基を、
R7′は低級アルキル基、アリール基またはアラル
キル基を表わし、R、R1、R2およびR3は前記と
同じ意味を表わす。) で示される化合物は第1方法で得られる化合物 と式() R7−X () (式中Xはハロゲン原子を表わし、R7は前記と同
じ意味を表わす。) で示される化合物とを反応させることによつて得
ることができる。ハロゲン原子として好ましいの
は臭素原子およびヨウ素原子である。 この反応は有機溶媒、たとえばベンゼン、トル
エン、キシレン、ジメチルホルムアミド、ジメチ
ルスルホキシド、ジオキサン、テトラヒドロフラ
ン、ピリジン、無水メタノール、無水エタノール
等、またはそれらの混合溶媒中室温乃至加熱下で
炭酸ナトリウム、炭酸カリウム等の脱酸剤の存在
下に行なうのが好ましい。 第4方法 本発明化合物のうち式() (式中R8は−(CH24−、−(CH25−または−
CH2CH2OCH2CH2−を表わし、R、R1、R2およ
びR3は前記と同じ意味を表わす。) で示される化合物は第1方法で得られる化合物 と式(XI) X−R8−X (XI) (式中R8およびXは前記と同じ意味を表わす。) で示される化合物とを第3方法と同様の反応条件
下で反応させることによつて得ることができる。 第5方法 本発明化合物のうち式(XII) (式中R、R1、R2、R3およびR6は前記と同じ意味
を表わす。) で示される化合物は化合物() をテトラヒドロフラン、エーテル等の有機溶媒中
で水素化アルミニウムリチウム、ジボラン等の還
元剤を用い、好ましくは加熱下で還元することに
よつて得ることができる。 以上の方法によつて得られた化合物を用いてさ
らに次の様な反応を行なうことができる。 (下記の構造式において Aは
Hydrogenation of the double bond present in the formula is also possible. Second method Formula () of the compound of the present invention (In the formula, R, R 1 , R 2 , R 3 and R 6 have the same meanings as above.) The compound represented by the formula is a compound obtained by the first method. It can be obtained by reacting with a carboxylic acid represented by the formula () R 6 -COOH () (in the formula, R 6 represents the same meaning as above) or a reactive derivative thereof. This reaction is preferably carried out in an organic solvent such as benzene, toluene, xylene, dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, pyridine, dioxane, etc., or a mixed solvent thereof, under cooling or at room temperature. When using the carboxylic acid (2), the reaction is preferably carried out in the presence of a condensing agent such as dicyclohexylcarbodiimide. Examples of reactive derivatives of carboxylic acids include acid halides such as acid chloride and acid bromide, mixed acid anhydrides with benzyl phosphoric acid, alkyl carbonic acid, pivalic acid, etc., p-nitrophenyl ester, thiophenyl ester, etc. Examples include active esters and acid anhydrides. Third method Among the compounds of the present invention, formula () or expression() (In the formula, R 7 is a lower alkyl group, an aryl group, an aralkyl group, or a lower alkoxycarbonyl group,
R 7 ' represents a lower alkyl group, aryl group or aralkyl group, and R, R 1 , R 2 and R 3 have the same meanings as above. ) is a compound obtained by the first method and a compound represented by the formula () R 7 -X () (wherein X represents a halogen atom and R 7 represents the same meaning as above). Preferred halogen atoms are bromine and iodine atoms. This reaction is carried out in an organic solvent such as benzene, toluene, xylene, dimethylformamide, dimethyl sulfoxide, dioxane, tetrahydrofuran, pyridine, anhydrous methanol, anhydrous ethanol, etc., or a mixed solvent thereof at room temperature or under heating. Preferably, this is carried out in the presence of a deoxidizing agent. Fourth method Among the compounds of the present invention, formula () (In the formula, R 8 is −(CH 2 ) 4 −, −(CH 2 ) 5 − or −
CH2CH2OCH2CH2- , and R, R1 , R2 and R3 have the same meanings as above. ) is a compound obtained by the first method and a compound represented by the formula (XI) X-R 8 -X (XI) (in the formula, R 8 and You can get it by twisting it. Fifth method Among the compounds of the present invention, formula (XII) (In the formula, R, R 1 , R 2 , R 3 and R 6 have the same meanings as above.) The compound represented by () can be obtained by reducing the compound in an organic solvent such as tetrahydrofuran or ether using a reducing agent such as lithium aluminum hydride or diborane, preferably under heating. Using the compound obtained by the above method, the following reactions can be further carried out. (In the structural formula below, A is

【式】を表わす。) (1) (上記式中R、R6およびR7′は前記と同じ意味を
表わす。) (2) (上記式中RおよびR6は前記と同じ意味を表わ
す。) (3) (上記式中Rは前記と同じ意味を表わす。) (4) (上記式中RおよびR6は前記と同じ意味を表わ
す。) 以下本発明化合物の製造について実施例により
説明する。 実施例 1 α−テルピネオール5.1gをジメチルホルムア
ミド−ベンゼン混液(容量比1:2)120mlに溶
かし、ナトリウムハイドライド(鉱油中50%懸濁
液)1.6gを加え、30分間加熱還流し、ついで冷
却後、p−フルオロニトロベンゼン4.7gを滴下
し、6時間加熱還流した。反応液を冷却後、ベン
ゼン200mlを加え、水および食塩水で洗浄し、ベ
ンゼン層を無水硫酸ナトリウムで乾燥した。溶媒
を減圧留去し、残留物をシリカゲルカラムクロマ
トグラフイーに付し、溶離液としてベンゼン−ヘ
キサン等量混液を用いて目的物を溶離し、溶出液
の溶媒を減圧留去すると4−(1−p−メンテン
−8−イルオキシ)ニトロベンゼン7.2gが得ら
れた。このものを酢酸エチル100mlに溶かし、10
%パラジウム炭素0.7gを加えて、水素雰囲気中
理論量の水素が吸収されるまでかきまぜながら反
応させた。パラジウム炭素を去後、溶媒を減圧
留去し、残留物を減圧下で精留すると4−(p−
メンタン−8−イルオキシ)アニリン5.07gが得
られた。 沸点 146〜148℃/0.3mmHg 元素分析値(C16H25NOとして) C(%) H(%) N(%) 理論値 77.68 10.19 5.66 実験値 77.73 10.20 5.64 実施例 2 4−(p−メンタン−8−イルオキシ)アニリ
ン6.2g、無水炭酸カリウム7gおよび1・5−
ジブロモペンタン5.75gを無水エタノール150ml
に順次加え、40時間加熱還流した。反応液を冷却
後、溶媒を減圧留去し、残留物にジクロロメタン
200mlおよび水150mlを加えた。ジクロロメタン層
を分取し、水および食塩水で洗浄し、無水硫酸ナ
トリウムで乾燥した。溶媒を減圧留去し、残留物
をシリカゲルカラムクロマトグラフイーに付し、
溶離液としてアンモニアで飽和したベンゼンを用
いて目的物を溶離し、溶出液の溶媒を減圧留去す
ると結晶状の1−〔4−(p−メンタン−8−イル
オキシ)フエニル〕ピペリジン5.77gが得られ
た。このものをエタノールで再結晶すると融点53
〜54℃の白色結晶が得られた。 元素分析値(C21H33NOとして) C(%) H(%) N(%) 理論値 79.95 10.54 4.44 実験値 79.90 10.83 4.37 実施例1におけるα−テルピネオールの代わり
に、他のアルコール化合物を用い、実施例1と同
様の処理をしてアニリン誘導体とし、ついで実施
例2と同様に1・5−ジブロモペンタンを反応さ
せ実施例3〜17の化合物を製造した。
Represents [formula]. ) (1) (R, R 6 and R 7 ' in the above formula have the same meanings as above.) (2) (R and R 6 in the above formula have the same meanings as above.) (3) (R in the above formula has the same meaning as above.) (4) (In the above formula, R and R 6 have the same meanings as above.) The production of the compounds of the present invention will be explained below with reference to Examples. Example 1 5.1 g of α-terpineol was dissolved in 120 ml of a dimethylformamide-benzene mixture (volume ratio 1:2), 1.6 g of sodium hydride (50% suspension in mineral oil) was added, heated under reflux for 30 minutes, then cooled and p- 4.7 g of fluoronitrobenzene was added dropwise, and the mixture was heated under reflux for 6 hours. After cooling the reaction solution, 200 ml of benzene was added and washed with water and brine, and the benzene layer was dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the residue was subjected to silica gel column chromatography. The target product was eluted using a mixture of equal volumes of benzene and hexane as an eluent. When the solvent of the eluate was distilled off under reduced pressure, 4-(1 7.2 g of -p-menthen-8-yloxy)nitrobenzene were obtained. Dissolve this in 100ml of ethyl acetate and
% palladium on carbon was added, and the mixture was stirred and reacted in a hydrogen atmosphere until the theoretical amount of hydrogen was absorbed. After removing the palladium on carbon, the solvent was distilled off under reduced pressure, and the residue was rectified under reduced pressure to obtain 4-(p-
5.07 g of menthan-8-yloxy)aniline were obtained. Boiling point 146-148℃/0.3mmHg Elemental analysis value (as C 16 H 25 NO) C (%) H (%) N (%) Theoretical value 77.68 10.19 5.66 Experimental value 77.73 10.20 5.64 Example 2 6.2 g of 4-(p-menthan-8-yloxy)aniline, 7 g of anhydrous potassium carbonate and 1.5-
Dibromopentane 5.75g and absolute ethanol 150ml
were sequentially added to the mixture and heated under reflux for 40 hours. After cooling the reaction solution, the solvent was distilled off under reduced pressure, and dichloromethane was added to the residue.
200 ml and 150 ml of water were added. The dichloromethane layer was separated, washed with water and brine, and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the residue was subjected to silica gel column chromatography.
The target product was eluted using benzene saturated with ammonia as an eluent, and the solvent of the eluate was distilled off under reduced pressure to obtain 5.77 g of crystalline 1-[4-(p-menthan-8-yloxy)phenyl]piperidine. It was done. When this substance is recrystallized with ethanol, the melting point is 53.
White crystals at ~54°C were obtained. Elemental analysis value (as C 21 H 33 NO) C (%) H (%) N (%) Theoretical value 79.95 10.54 4.44 Experimental value 79.90 10.83 4.37 Other alcohol compounds were used in place of α-terpineol in Example 1. The mixture was treated in the same manner as in Example 1 to obtain an aniline derivative, and then reacted with 1,5-dibromopentane in the same manner as in Example 2 to produce the compounds of Examples 3 to 17.

【表】【table】

【表】【table】

【表】【table】

【表】 実施例 18 4−(p−メンタン−8−イルオキシ)アニリン
1.23g、無水炭酸カリウム1.4g、1・4−ジブ
ロモブタン1.1gを無水エタノール50mlに順次加
え、42時間加熱還流した。以下実施例2と同様の
抽出・精製操作を行い。結晶状のN−〔4−(p−
メンタン−8−イルオキシ)フエニル〕ピロリジ
ン1.1gが得られた。このものをエタノールで再
結晶すると融点92〜93℃の白色結晶が得られた。 元素分析値(C20H31NOとして) C(%) H(%) N(%) 理論値 79.68 10.36 4.65 実験値 79.43 10.65 4.37 実施例 19 4−(p−メンタン−8−イルオキシ)アニリ
ン10gをテトラヒドロフラン−ピリジン等量混液
100mlに溶かし、氷冷下無水酢酸8mlを滴下し、
室温で一夜かきまぜた。反応液を氷300g中にあ
け、約2時間かきまぜ、析出した結晶を取し、
水で洗浄後、エタノール50mlで再結晶すると白色
結晶状の4−(p−メンタン−8−イルオキシ)
アセトアニリド6.7gが得られた。 融点 119〜120℃ 元素分析値(C18H27NOとして) C(%) H(%) N(%) 理論値 74.70 9.40 4.84 実験値 74.61 9.65 4.73 実施例1におけるα−テルピネオールの代わり
に、他のアルコール化合物を用い実施例1と同様
の処理をしてアニリン誘導体とし、ついで実施例
19と同様に無水酢酸を反応させ実施例20〜32の化
合物を製造した。
[Table] Example 18 4-(p-menthan-8-yloxy)aniline
1.23 g of anhydrous potassium carbonate, 1.4 g of anhydrous potassium carbonate, and 1.1 g of 1,4-dibromobutane were sequentially added to 50 ml of absolute ethanol, and the mixture was heated under reflux for 42 hours. The same extraction and purification operations as in Example 2 were then performed. Crystalline N-[4-(p-
1.1 g of menthan-8-yloxy)phenylpyrrolidine were obtained. When this product was recrystallized from ethanol, white crystals with a melting point of 92-93°C were obtained. Elemental analysis value (as C 20 H 31 NO) C (%) H (%) N (%) Theoretical value 79.68 10.36 4.65 Experimental value 79.43 10.65 4.37 Example 19 Mix 10 g of 4-(p-menthan-8-yloxy)aniline with equal amounts of tetrahydrofuran and pyridine.
Dissolve in 100ml, add 8ml of acetic anhydride dropwise under ice cooling,
Stir overnight at room temperature. Pour the reaction solution into 300g of ice, stir for about 2 hours, remove the precipitated crystals,
After washing with water and recrystallizing with 50 ml of ethanol, white crystalline 4-(p-menthan-8-yloxy) was obtained.
6.7 g of acetanilide was obtained. Melting point 119-120℃ Elemental analysis value (as C 18 H 27 NO) C (%) H (%) N (%) Theoretical value 74.70 9.40 4.84 Experimental value 74.61 9.65 4.73 Instead of α-terpineol in Example 1, other The alcohol compound was treated in the same manner as in Example 1 to obtain an aniline derivative, and then Example
Compounds of Examples 20 to 32 were produced by reacting acetic anhydride in the same manner as in Example 19.

【表】【table】

【表】【table】

【表】【table】

【表】 実施例19における無水酢酸の代わりに、無水イ
ソ酪酸、無水安息香酸を用いて実施例33と34の化
合物を製造した。
[Table] Compounds of Examples 33 and 34 were produced using isobutyric anhydride and benzoic anhydride in place of acetic anhydride in Example 19.

【表】 実施例 35 4−(p−メンタン−8−イルオキシ)アニリ
ン1gをテトラヒドロフラン−ピリジン等量混液
10gに溶かし、氷令下シクロヘキシルカルボニル
クロライド0.65gを滴下し、室温で一夜かきまぜ
た。反応液を氷60g中にあけ、約2時間かきま
ぜ、析出した結晶を取し、水で洗浄後、エタノ
ール10mlで再結晶すると白色結晶状のN−シクロ
ヘキシルカルボニル−4−(p−メンタン−8−
イルオキシ)アニリン1.02gが得られた。 融点 171〜172℃ 元素分析値(C23H35NO2として) C(%) H(%) N(%) 理論値 77.27 9.87 3.92 実験値 77.27 10.13 3.74 実施例35におけるシクロヘキシルカルボニルク
ロライドの代わりに、シンナミルカルボニルクロ
ライド、1−アダマンタニルカルボニルクロライ
ド、N・N−ジメチルカルバモイルクロライドを
用い実施例36〜38の化合物を製造した。
[Table] Example 35 A mixture of 1 g of 4-(p-menthan-8-yloxy)aniline and equal amounts of tetrahydrofuran and pyridine
The solution was dissolved in 10 g, 0.65 g of cyclohexylcarbonyl chloride was added dropwise under ice, and the mixture was stirred overnight at room temperature. Pour the reaction solution into 60 g of ice, stir for about 2 hours, collect the precipitated crystals, wash with water, and recrystallize with 10 ml of ethanol to obtain white crystals of N-cyclohexylcarbonyl-4-(p-menthane-8-
1.02 g of yloxy)aniline was obtained. Melting point 171-172℃ Elemental analysis value (as C 23 H 35 NO 2 ) C (%) H (%) N (%) Theoretical value 77.27 9.87 3.92 Experimental value 77.27 10.13 3.74 Instead of cyclohexyl carbonyl chloride in Example 35, Compounds of Examples 36 to 38 were produced using cinnamyl carbonyl chloride, 1-adamantanyl carbonyl chloride, and N.N-dimethylcarbamoyl chloride.

【表】 実施例1におけるα−テルピネオールの代わり
に、他のアルコール化合物を用い実施例1と同様
の処理をしてアニリン誘導体とし、ついでN・N
−ジメチルカルバモイルクロライドまたは1−ア
ダマンタンカルボニルクロライドを実施例35と同
様に反応させ実施例39〜41の化合物を製造した。
[Table] Instead of α-terpineol in Example 1, another alcohol compound was used and treated in the same manner as in Example 1 to obtain an aniline derivative, and then N.N.
-Dimethylcarbamoyl chloride or 1-adamantane carbonyl chloride was reacted in the same manner as in Example 35 to produce the compounds of Examples 39 to 41.

【表】 実施例 42 実施例36で得られたN−シンナモイル−4−
(p−メンタン−8−イルオキシ)アニリン750mg
を無水エタノール20mlに溶かし、10%パラジウム
炭素350mgを加えて、水素雰囲気中理論量の水素
が吸収されるまでかきまぜて反応させた。パラジ
ウム炭素を去後、溶媒を減圧留去し、残留物を
85%エタノールより再結晶すると白色結晶状の4
−(p−メンタン−8−イルオキシ)−N−(3−
フエニルプロピオニル)アニリン0.7gが得られ
た。 融点 96〜97℃ 元素分析値(C25H33NO2として) C(%) H(%) N(%) 理論値 79.11 8.76 3.69 実験値 78.99 8.91 3.68 実施例 43 4−(p−メンタン−8−イルオキシ)アニリ
ン2.5g、無水炭酸カリウム1.4g、ベンジルブロ
マイド1.7gを無水エタノール100mlに順次加え、
4時間室温で反応させ、ついで40時間加熱還流し
た。以下実施例2と同様の抽出、精製操作により
油状のN−ベンジル−4−(p−メンタン−8−
イルオキシ)アニリン0.95gが得られた。この生
成物を無水エーテル25mlに溶かし、冷去下5規定
塩酸1mlを加え冷却放置すると塩酸塩0.8gが得
られた。これをジクロロロメタン−酢酸エチル混
液で再結晶すると融点137〜138℃の白色結晶状の
塩酸塩が得られた。 元素分析値(C23H32NOClとして) C(%) H(%) N(%) 理論値 73.87 8.63 3.75 実験値 73.55 8.72 3.54 実施例 44 実施例43におけるベンジルブロマイドの代わり
に、1−ブロモブタンを用いて同様に処理すると
N−ブチル−4−(p−メンタン−8−イルオキ
シ)アニリン・塩酸塩が得られた。 融点 138〜139℃ 元素分析値(C20H34NOClとして) C(%) H(%) N(%) 理論値 70.66 10.08 4.12 実験値 70.46 10.28 3.91 実施例 45 4−(p−メンタン−8−イルオキシ)アニリ
ン5gを無水ピンジン50mlに溶かし、氷冷下かき
まぜながらクロル炭酸エチル4mlを滴下した。4
℃で一夜かきまぜた後、反応液を氷水300mlにあ
け、生じた油状物をエーテルで抽出し、抽出液
を、水、2%塩酸、水、食塩水で順次洗浄し、無
水硫酸マグネシウムで乾燥した。溶媒を減圧留去
し、得られた結晶をメタノール20mlで再結晶する
と白色結晶のN−エトキシカルボニル−4−(p
−メンタン−8−イルオキシ)アニリン3.5gが
得られた。 融点 65〜66℃ 元素分析値(C19H29NO3として) C(%) H(%) N(%) 理論値 71.44 9.15 4.38 実験値 71.46 9.37 4.54 なお再結晶母液よりさらに1.5gの目的物を得
ることができた。 実施例 46 水素化アルミニウムリチウム0.5gに無水テト
ラヒドロフラン6mlを加えた懸濁液に、撹拌下、
N−エトキシカルボニル−4−(p−メンタン−
8−イルオキシ)アニリン3.2gを無水テトラヒ
ドロフラン60mlに溶かした溶液を約2時間かけて
滴下し、ついで5時間加熱還流した。反応液を氷
冷後、水0.6ml、15%水酸化ナトリウム水溶液1
ml、水2mlを順次少しづつ加えた。不溶物を去
後、溶媒を減圧留去し、残留物をエーテルで抽出
した。抽出液を水で洗浄し、無水硫酸マグネシウ
ムで乾燥し、溶媒を減圧留去した。残留物をシリ
カゲルカラムクロマトグラフイーに付し、アンモ
ニア飽和ベンゼンを溶離液として用いて目的物を
溶離した。溶出液の溶媒を減圧留去し、残つた油
状物を減圧下に精留すると4−(p−メンタン−
8−イルオキシ)−N−メチルアニリン1.22gが
得られた 沸点 148〜151℃/0.6mmHg 元素分析値(C17H27NOとして) C(%) H(%) N(%) 理論値 78.11 10.41 5.36 実験値 78.08 10.80 5.51 実施例 47 N−メチル−4−(p−メンタン−8−イルオ
キシ)アニリン430mgを無水テトラヒドロフラン
5mlを溶かし、無水酢酸300mg、無水ピリジン0.8
mlを加え、室温で一夜かきまぜた。反応液を氷水
30mlにあけ、得られた白色結晶を石油エーテル5
mlで再結晶すると白色結晶状の4−(p−メンタ
ン−8−イルオキシ)−N−メチルアセトアニリ
ド350mgが得られた。 融点 70〜71℃ 元素分析値(C19H29NO2として) C(%) H(%) N(%) 理論値 75.21 9.63 4.62 実験値 75.01 9.96 4.41 実施例 48 4−(p−メンタン−8−イルオキシ)アセト
アニリド1gを無水エタノール20mlに溶かし、
tert−ブトキシカリウム0.4g、ベンジルブロマ
イド0.6gを加え、室温で24時間かきまぜた。溶
媒を減圧留去し、残留物をジクロロメタン、水で
処理し、ジクロロメタン層を水、食塩水で洗浄
し、無水硫酸マグネシウムで乾燥した。溶媒を減
圧留去し、得られた油状物をシリカゲルカラムク
ロマトグラフイーに付し、アンモニア飽和ベンゼ
ンを溶離液として用いて目的を溶離した。溶出液
の溶媒を減圧留去し、得られたシロツプ状物を減
圧下に精留するとN−ベンジル−4−(p−メン
タン−8−イルオキシ)アセトアニリド1.15gが
得られた。 沸点 195〜200℃/0.6mmHg 元素分析値(C25H33NO2として) C(%) H(%) N(%) 理論値 79.11 8.76 3.69 実験値 79.49 8.96 3.94 実施例 49 4−(p−メンタン−8−イルオキシ)アニリ
ン2.5gを無水エタノール80mlに溶かし、無水炭
酸カリウム2.8gを加え、室温で撹拌下、ヨウ化
メチル2.8gを無水エタノール10mlに溶かした溶
液を滴下した。一夜加熱還流した後、溶媒を減圧
留去し、ジクロロメタンで抽出した。抽出液を
水、食塩水で洗浄し、無水硫酸マグネシウムで乾
燥し、溶媒を減圧留去した。酸留物をエーテルで
抽出し、不溶なアンモニウム塩を除き、エーテル
を除去後、得られた油状物をシリカゲルカラムク
ロマトグラフイーに付し、アンモニア飽和ベンゼ
ンを溶離液として用いて目的物を溶離した。溶出
液を減圧留去し、残つた油状物を乾燥エーテル50
mlに溶かし、5規定塩酸−エタノール混液1mlを
加えると結晶状の4−(p−メンタン−8−イル
オキシ)−N・N−ジメチルアニリン・塩酸塩1.8
gが得られた。これをジロロメタン−酢酸エチル
混液で再結晶すると融点148〜149℃を示す白色結
晶が得られた。 元素分析値(C18H30NOClとして) C(%) H(%) N(%) 理論値 69.32 9.70 4.49 実験値 69.02 9.92 4.51 実施例 50 4−(p−メンタン−8−イルオキシ)−N・N
−ジメチルアニリン・塩酸塩を含むエーテル溶液
を炭酸水素ナトリウム水と処理して得た残留物1
gを無水エタノール30mlに溶かし、ヨウ化メチル
5mlを加え、一夜加熱還流した。溶媒および過剰
のヨウ化メチルを減圧留去後、残留物をジクロロ
メタンで抽出し、抽出液を水、食塩水で洗浄し、
無水硫酸マグネシウムで乾燥した。溶液を減圧下
で濃縮し、過剰のエーテルを加え、析出する沈殿
を取し、ジクロロメタン−エーテル混液で再結
晶すると白色結晶状の4−(p−メンタン−8−
イルオキシ)−N・N・N−トリメチルアニリニ
ウム・ヨウ化物0.9gが得られた。 融点 179〜180℃ 元素分析値(C19H32NOIとして) C(%) H(%) N(%) 理論値 54.68 7.73 3.36 実験値 54.34 7.91 3.25 実施例 51 4−(p−メンタン−8−イルオキシ)アセト
アニリド580mgを無水テトラヒドロフラン10mlに
溶かした溶液を、水素化アルミニウムリチウム
100mgと無水テトラヒドロフラン1mlからなる懸
濁液中に撹拌下滴下した。5時間加熱還流し、冷
去下に水0.1ml、15%水酸化ナトリウム水溶液0.1
ml、水0.3mlを順次加え、不溶物を去し、溶媒
を減圧留去した。残留物をシリカゲルカラムクロ
マトグラフイーに付し、アンモニア飽和ベンゼン
を溶離液として用いて目的物を溶離した。溶出液
を減圧下に濃縮し、ついで減圧下に精留するとN
−エチル−4−(p−メンタン−8−イルオキ
シ)アニリン300mgが得られた。 融点 143〜145℃/0.35mmHg 元素分析値(C18H29NOとして) C(%) H(%) N(%) 理論値 78.49 10.61 5.09 実験値 78.31 10.75 5.41 実施例 52 シス−p−メンタン−8−オール31.28gをジ
メチルホルムアミド−ベンゼン混液(容量比1:
2)670mlに溶かし、ナトリウムハイドライド
(鉱油中60%懸濁液)8.0gを加え、30分間加熱還
流し、ついで冷却後、p−フルオロニトロベンゼ
ン28.2gを滴下し、6時間加熱還流した。反応液
を冷却後、ベンゼン400mlを加え、水および塩化
ナトリウム水溶液で洗浄し、ベンゼン層を無水硫
酸ナトリウムで乾燥した。溶媒を減圧留去後、残
留物をシリカゲルカラムクロマトグラフイーに付
し、ベンゼン−ヘキサン等量混液を用いて目的物
を溶離し、溶出液の溶媒を減圧留去するとシス−
4−(p−メンタン−8−イルオキシ)ニトロベ
ンゼン−(沸点 180〜183℃/0.7mmHg)49gが
得られた。 この生成物44gを酢酸エチル200mlに溶かし、
10%パラジウム炭素2gを加えて、加圧下水素雰
囲気中、理論量の水素が吸収されるまでかきまぜ
ながら反応させた。パラジウム炭素を去後、溶
媒を減圧留去し、残留物を減圧下で精留するとシ
ス−4−(p−メンタン−8−イルオキシ)アニ
リン39.4gが得られた。 沸点 152〜154℃/1mmHg 元素分析値(C16H25NOとして) C(%) H(%) N(%) 理論値 77.68 10.19 5.66 実験値 77.70 10.22 5.65 実施例 53 シス−4−(p−メンタン−8−イルオキシ)
アニリン30g、無水炭酸カリウム25.2gおよび
1.5−ジブロモペンタン33.5gを無水エタノール
150mlに順次加え、15時間加熱還流した。反応液
を冷却後、溶媒を減圧留去し、残留物にジクロロ
メタン500mlおよび水500mlを加え、ジクロロメタ
ン層を分取し、水および塩化ナトリウム水溶液で
洗浄後、無水硫酸ナトリウムで乾燥した。溶媒を
減圧留去後、残留物をシリカゲルカラムクロマト
グラフイーに付し、溶離液としてアンモニアで飽
和したベンゼンを用いて目的物を溶離し、溶出液
の溶媒を減圧留去すると結晶状のシス−1−〔4
−(p−メンタン−8−イルオキシ)フエニル〕
ピペリジン23gが得られた。このものをエタノー
ルで再結晶すると融点78−79℃の白色結晶が得ら
れた。 元素分析値(C21H33NOとして) C(%) H(%) N(%) 理論値 79.95 10.54 4.44 実験値 79.83 10.98 4.36 実施例 54 実施例52において、シス−p−メンタン−8−
オールの代わりにトランス−p−メンタン−8−
オールを用い、トランス−4−(p−メンタン−
8−イルオキシ)ニトロベンゼン(沸点168−171
℃/1mmHg)を得、実施例52と同様の処理をし
てトランス−4−(p−メンタン−8−イルオキ
シ)アニリンが得られた。 沸点 141〜143℃/0.6mmHg 元素分析値(C16H25NOとして) C(%) H(%) N(%) 理論値 77.68 10.19 5.66 実験値 77.86 10.31 5.64 実施例 55 実施例53においてシス−4−(p−メンタン−
8−イルオキシ)アニリンの代わりにトランス−
4−(p−メンタン−8−イルオキシ)アニリン
を用い、実施例53と同様の処理をしてトランス−
1−〔4−(p−メンタン−8−イルオキシ)フエ
ニル〕ピペリジンの結晶が得られた。 融点 62−63℃ 元素分析値(C21H33NOとして) C(%) H(%) N(%) 理論値 79.95 10.54 4.44 実験値 80.00 10.87 4.39 実施例 56 トランス−4−(p−メンタン−8−イルオキ
シ)アニリン21gを無水ピリジン40mlと無水ジク
ロロメタン100mlの混液に溶かし、氷冷下かきま
ぜながらクロロ炭酸エチル18.5gを滴下した。4
℃で一夜かきまぜた後、反応液を氷水300mlにあ
け、ジクロロメタン層を分取した。 水層をジクロロメタン80mlで再抽出し、抽出液
を先に分取した。ジクロロメタン溶液と合し、こ
れを水、2%塩酸、水、塩化ナトリウム水溶液で
順次洗浄し、無水硫酸マグネシウムで乾燥した。
溶媒を減圧留去し、得られた結晶をメタノール80
mlで再結晶するとトランス−N−エトキシカルボ
ニル−4−(p−メンタン−8−イルオキシ)ア
ニリン19.5gが得られた。 融点 76〜77℃ 元素分析値(C19H29NO3として) C(%) H(%) N(%) 理論値 71.44 9.15 4.38 実験値 71.87 9.43 4.35 実施例 57 実施例56においてトランス−4−(p−メンタ
ン−8−イルオキシ)アニリンの代わりにシス−
4−(p−メンタン−8−イルオキシ)アニリン
を用い、実施例56と同様の処理をしてシス−N−
エトキシカルボニル−4−(p−メンタン−8−
イルオキシ)アニリンの含メタノール結晶が得ら
れた。このものを減圧乾燥し、メタノールを除去
するとシス−N−エトキシカルボニル−4−(p
−メンタン−8−イルオキシ)アニリンが油状物
として得られた。 元素分析値(C19H29NO3として) C(%) H(%) N(%) 理論値 71.44 9.15 4.38 実験値 71.15 9.37 4.36 核磁気共鳴スペクトル(CDCl3)(内部標準
TMS) δ(ppm):0.99(
[Table] Example 42 N-cinnamoyl-4- obtained in Example 36
(p-menthan-8-yloxy)aniline 750mg
was dissolved in 20 ml of absolute ethanol, 350 mg of 10% palladium on carbon was added, and the mixture was stirred and reacted in a hydrogen atmosphere until the theoretical amount of hydrogen was absorbed. After removing the palladium on carbon, the solvent was distilled off under reduced pressure and the residue was
Recrystallization from 85% ethanol gives white crystalline 4.
-(p-menthan-8-yloxy)-N-(3-
0.7 g of phenylpropionyl)aniline was obtained. Melting point 96-97℃ Elemental analysis value (as C 25 H 33 NO 2 ) C (%) H (%) N (%) Theoretical value 79.11 8.76 3.69 Experimental value 78.99 8.91 3.68 Example 43 2.5 g of 4-(p-menthan-8-yloxy)aniline, 1.4 g of anhydrous potassium carbonate, and 1.7 g of benzyl bromide were sequentially added to 100 ml of absolute ethanol.
The reaction was allowed to proceed at room temperature for 4 hours, and then heated under reflux for 40 hours. The same extraction and purification operations as in Example 2 yielded oily N-benzyl-4-(p-menthane-8-
0.95 g of yloxy)aniline was obtained. This product was dissolved in 25 ml of anhydrous ether, and while cooling, 1 ml of 5N hydrochloric acid was added and left to cool, yielding 0.8 g of hydrochloride. This was recrystallized from a dichloromethane-ethyl acetate mixture to obtain a white crystalline hydrochloride with a melting point of 137-138°C. Elemental analysis value (as C 23 H 32 NOCl) C (%) H (%) N (%) Theoretical value 73.87 8.63 3.75 Experimental value 73.55 8.72 3.54 Example 44 When the same treatment was performed using 1-bromobutane instead of benzyl bromide in Example 43, N-butyl-4-(p-menthan-8-yloxy)aniline hydrochloride was obtained. Melting point 138-139℃ Elemental analysis value (as C 20 H 34 NOCl) C (%) H (%) N (%) Theoretical value 70.66 10.08 4.12 Experimental value 70.46 10.28 3.91 Example 45 5 g of 4-(p-menthan-8-yloxy)aniline was dissolved in 50 ml of anhydrous pintane, and 4 ml of ethyl chlorocarbonate was added dropwise while stirring under ice cooling. 4
After stirring overnight at ℃, the reaction solution was poured into 300 ml of ice water, the resulting oil was extracted with ether, the extract was washed successively with water, 2% hydrochloric acid, water, and brine, and dried over anhydrous magnesium sulfate. . The solvent was distilled off under reduced pressure, and the resulting crystals were recrystallized from 20 ml of methanol to give white crystals of N-ethoxycarbonyl-4-(p
3.5 g of -menthan-8-yloxy)aniline were obtained. Melting point 65-66℃ Elemental analysis value (as C 19 H 29 NO 3 ) C (%) H (%) N (%) Theoretical value 71.44 9.15 4.38 Experimental value 71.46 9.37 4.54 In addition, 1.5 g of target material was obtained from the recrystallization mother liquor I was able to get Example 46 To a suspension of 0.5 g of lithium aluminum hydride and 6 ml of anhydrous tetrahydrofuran, while stirring,
N-ethoxycarbonyl-4-(p-menthane-
A solution of 3.2 g of 8-yloxy)aniline dissolved in 60 ml of anhydrous tetrahydrofuran was added dropwise over about 2 hours, and then heated under reflux for 5 hours. After cooling the reaction solution on ice, add 0.6 ml of water and 15% aqueous sodium hydroxide solution.
ml and 2 ml of water were added little by little. After removing the insoluble materials, the solvent was distilled off under reduced pressure, and the residue was extracted with ether. The extract was washed with water, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The residue was subjected to silica gel column chromatography, and the target product was eluted using ammonia-saturated benzene as an eluent. The solvent of the eluate was distilled off under reduced pressure, and the remaining oil was rectified under reduced pressure to obtain 4-(p-menthane-
Boiling point at which 1.22g of (8-yloxy)-N-methylaniline was obtained 148-151℃/0.6mmHg Elemental analysis value (as C 17 H 27 NO) C (%) H (%) N (%) Theoretical value 78.11 10.41 5.36 Experimental value 78.08 10.80 5.51 Example 47 Dissolve 430 mg of N-methyl-4-(p-menthan-8-yloxy)aniline in 5 ml of anhydrous tetrahydrofuran, 300 mg of acetic anhydride, and 0.8 mg of anhydrous pyridine.
ml and stirred overnight at room temperature. Pour the reaction solution into ice water.
Pour the obtained white crystals into 30 ml of petroleum ether.
ml to obtain 350 mg of white crystalline 4-(p-menthan-8-yloxy)-N-methylacetanilide. Melting point 70-71℃ Elemental analysis value (as C 19 H 29 NO 2 ) C (%) H (%) N (%) Theoretical value 75.21 9.63 4.62 Experimental value 75.01 9.96 4.41 Example 48 Dissolve 1 g of 4-(p-menthan-8-yloxy)acetanilide in 20 ml of absolute ethanol,
0.4 g of tert-butoxypotassium and 0.6 g of benzyl bromide were added, and the mixture was stirred at room temperature for 24 hours. The solvent was distilled off under reduced pressure, and the residue was treated with dichloromethane and water. The dichloromethane layer was washed with water and brine, and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the resulting oil was subjected to silica gel column chromatography, and the desired product was eluted using ammonia-saturated benzene as an eluent. The solvent of the eluate was distilled off under reduced pressure, and the resulting syrupy substance was rectified under reduced pressure to obtain 1.15 g of N-benzyl-4-(p-menthan-8-yloxy)acetanilide. Boiling point 195-200℃/0.6mmHg Elemental analysis value (as C 25 H 33 NO 2 ) C (%) H (%) N (%) Theoretical value 79.11 8.76 3.69 Experimental value 79.49 8.96 3.94 Example 49 2.5 g of 4-(p-menthan-8-yloxy)aniline was dissolved in 80 ml of absolute ethanol, 2.8 g of anhydrous potassium carbonate was added, and a solution of 2.8 g of methyl iodide dissolved in 10 ml of absolute ethanol was added dropwise while stirring at room temperature. . After heating under reflux overnight, the solvent was distilled off under reduced pressure, and the mixture was extracted with dichloromethane. The extract was washed with water and brine, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The acid distillate was extracted with ether, insoluble ammonium salts were removed, and the ether was removed. The resulting oil was subjected to silica gel column chromatography, and the target product was eluted using ammonia-saturated benzene as the eluent. . The eluate was distilled off under reduced pressure, and the remaining oil was dissolved in dry ether 50%.
ml and add 1 ml of 5N hydrochloric acid-ethanol mixture to obtain crystalline 4-(p-menthan-8-yloxy)-N·N-dimethylaniline hydrochloride 1.8
g was obtained. When this was recrystallized from a dichloromethane-ethyl acetate mixture, white crystals with a melting point of 148-149°C were obtained. Elemental analysis value (as C 18 H 30 NOCl) C (%) H (%) N (%) Theoretical value 69.32 9.70 4.49 Experimental value 69.02 9.92 4.51 Example 50 4-(p-menthan-8-yloxy)-N・N
- Residue 1 obtained by treating an ether solution containing dimethylaniline hydrochloride with aqueous sodium bicarbonate
g was dissolved in 30 ml of absolute ethanol, 5 ml of methyl iodide was added, and the mixture was heated under reflux overnight. After distilling off the solvent and excess methyl iodide under reduced pressure, the residue was extracted with dichloromethane, and the extract was washed with water and brine.
It was dried with anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, excess ether was added, the precipitate was collected, and recrystallized from a dichloromethane-ether mixture to give white crystalline 4-(p-menthane-8-
0.9 g of N.N.N-trimethylanilinium iodide was obtained. Melting point 179-180℃ Elemental analysis value (as C 19 H 32 NOI) C (%) H (%) N (%) Theoretical value 54.68 7.73 3.36 Experimental value 54.34 7.91 3.25 Example 51 A solution of 580 mg of 4-(p-menthan-8-yloxy)acetanilide dissolved in 10 ml of anhydrous tetrahydrofuran was added to lithium aluminum hydride.
The mixture was added dropwise to a suspension of 100 mg and 1 ml of anhydrous tetrahydrofuran while stirring. Heating under reflux for 5 hours, cooling and adding 0.1 ml of water and 0.1 ml of 15% aqueous sodium hydroxide solution.
ml and 0.3 ml of water were sequentially added to remove insoluble matter, and the solvent was distilled off under reduced pressure. The residue was subjected to silica gel column chromatography, and the target product was eluted using ammonia-saturated benzene as an eluent. The eluate is concentrated under reduced pressure and then rectified under reduced pressure to obtain N
300 mg of -ethyl-4-(p-menthan-8-yloxy)aniline was obtained. Melting point 143-145℃/0.35mmHg Elemental analysis value (as C 18 H 29 NO) C (%) H (%) N (%) Theoretical value 78.49 10.61 5.09 Experimental value 78.31 10.75 5.41 Example 52 31.28 g of cis-p-menthan-8-ol was added to a dimethylformamide-benzene mixture (volume ratio 1:
2) Dissolved in 670 ml, added 8.0 g of sodium hydride (60% suspension in mineral oil), heated under reflux for 30 minutes, cooled, added dropwise 28.2 g of p-fluoronitrobenzene, and heated under reflux for 6 hours. After cooling the reaction solution, 400 ml of benzene was added, washed with water and an aqueous sodium chloride solution, and the benzene layer was dried over anhydrous sodium sulfate. After distilling off the solvent under reduced pressure, the residue was subjected to silica gel column chromatography, and the target product was eluted using a mixture of equal volumes of benzene and hexane. When the solvent of the eluate was distilled off under reduced pressure, cis-
49 g of 4-(p-menthan-8-yloxy)nitrobenzene (boiling point 180-183°C/0.7 mmHg) was obtained. Dissolve 44g of this product in 200ml of ethyl acetate,
2 g of 10% palladium on carbon was added and reacted under pressure in a hydrogen atmosphere with stirring until the theoretical amount of hydrogen was absorbed. After removing the palladium on carbon, the solvent was distilled off under reduced pressure, and the residue was rectified under reduced pressure to obtain 39.4 g of cis-4-(p-menthan-8-yloxy)aniline. Boiling point 152-154℃/1mmHg Elemental analysis value (as C 16 H 25 NO) C (%) H (%) N (%) Theoretical value 77.68 10.19 5.66 Experimental value 77.70 10.22 5.65 Example 53 cis-4-(p-menthan-8-yloxy)
30g of aniline, 25.2g of anhydrous potassium carbonate and
33.5g of 1.5-dibromopentane in absolute ethanol
The mixture was sequentially added to 150 ml and heated under reflux for 15 hours. After cooling the reaction solution, the solvent was distilled off under reduced pressure, and 500 ml of dichloromethane and 500 ml of water were added to the residue. The dichloromethane layer was separated, washed with water and an aqueous sodium chloride solution, and then dried over anhydrous sodium sulfate. After distilling off the solvent under reduced pressure, the residue was subjected to silica gel column chromatography, and the target product was eluted using benzene saturated with ammonia as an eluent. When the solvent of the eluate was distilled off under reduced pressure, crystalline cis- 1-[4
-(p-menthan-8-yloxy)phenyl]
23 g of piperidine was obtained. When this product was recrystallized from ethanol, white crystals with a melting point of 78-79°C were obtained. Elemental analysis value (as C 21 H 33 NO) C (%) H (%) N (%) Theoretical value 79.95 10.54 4.44 Experimental value 79.83 10.98 4.36 Example 54 In Example 52, cis-p-menthane-8-
trans-p-menthane-8- instead of ol
trans-4-(p-menthane-
8-yloxy)nitrobenzene (boiling point 168-171
C/1 mmHg) and treated in the same manner as in Example 52 to obtain trans-4-(p-menthan-8-yloxy)aniline. Boiling point 141-143℃/0.6mmHg Elemental analysis value (as C 16 H 25 NO) C (%) H (%) N (%) Theoretical value 77.68 10.19 5.66 Experimental value 77.86 10.31 5.64 Example 55 In Example 53, cis-4-(p-menthane-
trans-8-yloxy)aniline instead of
Using 4-(p-menthan-8-yloxy)aniline, a trans-
Crystals of 1-[4-(p-menthan-8-yloxy)phenyl]piperidine were obtained. Melting point 62-63℃ Elemental analysis value (as C 21 H 33 NO) C (%) H (%) N (%) Theoretical value 79.95 10.54 4.44 Experimental value 80.00 10.87 4.39 Example 56 21 g of trans-4-(p-menthan-8-yloxy)aniline was dissolved in a mixture of 40 ml of anhydrous pyridine and 100 ml of anhydrous dichloromethane, and 18.5 g of ethyl chlorocarbonate was added dropwise while stirring under ice cooling. 4
After stirring at °C overnight, the reaction solution was poured into 300 ml of ice water, and the dichloromethane layer was separated. The aqueous layer was re-extracted with 80 ml of dichloromethane, and the extract was separated first. This was combined with a dichloromethane solution, washed successively with water, 2% hydrochloric acid, water, and an aqueous sodium chloride solution, and dried over anhydrous magnesium sulfate.
The solvent was distilled off under reduced pressure, and the resulting crystals were mixed with methanol 80
19.5 g of trans-N-ethoxycarbonyl-4-(p-menthan-8-yloxy)aniline was obtained. Melting point 76-77℃ Elemental analysis value (as C 19 H 29 NO 3 ) C (%) H (%) N (%) Theoretical value 71.44 9.15 4.38 Experimental value 71.87 9.43 4.35 Example 57 In Example 56, trans-4-(p-menthan-8-yloxy)aniline was replaced by cis-
Using 4-(p-menthan-8-yloxy)aniline, cis-N-
Ethoxycarbonyl-4-(p-menthane-8-
Methanol-containing crystals of yloxy)aniline were obtained. After drying this product under reduced pressure to remove methanol, cis-N-ethoxycarbonyl-4-(p
-menthan-8-yloxy)aniline was obtained as an oil. Elemental analysis value (as C 19 H 29 NO 3 ) C (%) H (%) N (%) Theoretical value 71.44 9.15 4.38 Experimental value 71.15 9.37 4.36 Nuclear magnetic resonance spectrum (CDCl 3 ) (internal standard
TMS) δ (ppm): 0.99 (

【式】3H、 d) 1.20([Formula] 3H, d) 1.20 (

【式】6H、s) 1.30(CH3−CH2−O−、3H、t) 1.0〜2.1([Formula] 6H, s) 1.30 (CH 3 -CH 2 -O-, 3H, t) 1.0-2.1 (

【式】10H、m) 4.24(CH3−CH2−O−、2H、q) 6.72(−NHCO−、1H、s) 6.95、7.3([Formula] 10H, m) 4.24 (CH 3 -CH 2 -O-, 2H, q) 6.72 (-NHCO-, 1H, s) 6.95, 7.3 (

【式】4H、A2B2q) 実施例 58 トランス−N−エトキシカルボニル−4−(p
−メンタン−8−イルオキシ)アニリン2.1gを
1規定の水酸化カリウム−95%エタノール溶液47
mlに溶かし、6時間加熱還流した。反応液よりエ
タノールを減圧留去し、残留物にエーテル50ml、
水50mlを加え、反応生成物をエーテルで抽出し
た。抽出液を水および塩化ナトリウム水溶液で洗
浄し、無水硫酸マグネシウムで乾燥後、エーテル
を留去すると、トランス−4−(p−メンタン−
8−イルオキシ)アニリン1.75gが得られた。 この生成物1.7gを無水炭酸カリウム2g、1.5
−ジブロモペンタン1.7gと共に無水エタノール
50mlに加え16時間加熱還流し、反応液を実施例53
と同様に処理するとトランス−1−〔4−(p−メ
ンタン−8−イルオキシ)フエニル〕ピペリジン
の結晶0.95gが得られた。 融点 62−63℃ この結晶の赤外吸収スペクトル、核磁気共鳴ス
ペクトル(1H、13C)および質量スペクトルは実
施例55で得た結晶のスペクトル類と良く一致し
た。 実施例 59 実施例58においてトランス−N−エトキシカル
ボニル−4−(p−メンダン−8−イルオキシ)−
アニリンの代わりにシス−N−エトキシカルボニ
ル−4−(p−メンタン−8−イルオキシ)アニ
リンを用い、実施例58と同様に処理をして、シス
−1−〔4−(p−メンタン−8−イルオキシ)フ
エニル〕ピペリジンの結晶が得られた。 融点 78−79℃ この結晶の赤外吸収スペクトル、核磁気共鳴ス
ペクトル(1H、13C)および質量スペクトルは実
施例53で得た結晶のスペクトル類と良く一致し
た。
[Formula] 4H, A 2 B 2 q) Example 58 trans-N-ethoxycarbonyl-4-(p
- Menthan-8-yloxy)aniline 2.1g in 1N potassium hydroxide-95% ethanol solution 47
ml and heated under reflux for 6 hours. Ethanol was distilled off from the reaction solution under reduced pressure, and 50 ml of ether was added to the residue.
50 ml of water was added and the reaction product was extracted with ether. The extract was washed with water and an aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the ether was distilled off to give trans-4-(p-menthane-
1.75 g of 8-yloxy)aniline were obtained. 1.7 g of this product, 2 g of anhydrous potassium carbonate, 1.5 g
- Absolute ethanol with 1.7 g of dibromopentane
50 ml and heated under reflux for 16 hours, and the reaction solution was diluted with Example 53.
When treated in the same manner as above, 0.95 g of crystals of trans-1-[4-(p-menthan-8-yloxy)phenyl]piperidine were obtained. Melting point: 62-63° C. The infrared absorption spectrum, nuclear magnetic resonance spectrum ( 1 H, 13 C), and mass spectrum of this crystal were in good agreement with the spectra of the crystal obtained in Example 55. Example 59 In Example 58, trans-N-ethoxycarbonyl-4-(p-mendan-8-yloxy)-
Using cis-N-ethoxycarbonyl-4-(p-menthan-8-yloxy)aniline instead of aniline, the same treatment as in Example 58 was carried out to obtain cis-1-[4-(p-menthane-8-yloxy)aniline. -yloxy)phenyl]piperidine crystals were obtained. Melting point: 78-79°C The infrared absorption spectrum, nuclear magnetic resonance spectrum ( 1 H, 13 C), and mass spectrum of this crystal were in good agreement with the spectra of the crystal obtained in Example 53.

Claims (1)

【特許請求の範囲】 1 一般式 [式中、Rは水素原子を、R1は水素原子または低
級アルキル基を、R2は低級アルキル基で置換さ
れていてもよいシクロペンチル基もしくはシクロ
ヘキシル基;炭素数1〜20個のアルキル基、フエ
ニル基、またはベンジル基を、R3は水素原子、
低級アルキル基、低級アルキル基で置換されてい
てもよいシクロペンチル基もしくはシクロヘキシ
ル基、フエニル基、またはベンジル基を、R4
水素原子、低級アルキル基、アラルキル基、また
は低級アルコキシカルボニル基を、R5は水素原
子、低級アルキル基、式−COR6(式中R6は低級
アルキル基、シクロヘキシル基、アリール基、ア
ラルキル基、アラルケニル基、低級アルキル基で
置換されていてもよいアミノ基、または有橋炭化
水素基を表わす) で示される基を表わす。但し、前記R2とR3は隣
接炭素原子と一体となつて低級アルキル基で置換
されていてもよいシクロヘキサン環を形成しても
よく、また前記R4とR5は隣接窒素原子と一体と
なつてピリジン環、ピペリジン環またはモルホリ
ン環を形成してもよい。] で示されるアミノフエニルエーテル化合物、また
はその薬理的に許容される酸付加塩若しくはハロ
ゲン化アルキルとの第4級アンモニウム塩。 2 Rが水素原子、R1およびR3が低級アルキル
基、R2が低級アルキル基で置換されたシクロヘ
キシル基、R4とR5が隣接窒素原子と一体となつ
てピペリジン環を形成している特許請求の範囲第
1項記載の化合物。 3 RおよびR4が水素原子、R1およびR3が低級
アルキル基、R2が低級アルキル基で置換された
シクロヘキシル基、R5がアセチル基である特許
請求の範囲第1項記載の化合物。
[Claims] 1. General formula [In the formula, R is a hydrogen atom, R 1 is a hydrogen atom or a lower alkyl group, R 2 is a cyclopentyl group or a cyclohexyl group that may be substituted with a lower alkyl group; an alkyl group having 1 to 20 carbon atoms, phenyl group or benzyl group, R 3 is hydrogen atom,
A lower alkyl group, a cyclopentyl group or cyclohexyl group optionally substituted with a lower alkyl group, a phenyl group, or a benzyl group, R 4 is a hydrogen atom, a lower alkyl group, an aralkyl group, or a lower alkoxycarbonyl group, R 5 is a hydrogen atom, a lower alkyl group, the formula -COR 6 (in the formula, R 6 is a lower alkyl group, a cyclohexyl group, an aryl group, an aralkyl group, an aralkenyl group, an amino group optionally substituted with a lower alkyl group, or a bridged (represents a hydrocarbon group) However, R 2 and R 3 may be combined with adjacent carbon atoms to form a cyclohexane ring which may be substituted with a lower alkyl group, and R 4 and R 5 may be combined with adjacent nitrogen atoms to form a cyclohexane ring which may be substituted with a lower alkyl group. They may be combined to form a pyridine ring, piperidine ring or morpholine ring. ] The aminophenyl ether compound represented by these, or its pharmacologically acceptable acid addition salt or quaternary ammonium salt with an alkyl halide. 2 R is a hydrogen atom, R 1 and R 3 are lower alkyl groups, R 2 is a cyclohexyl group substituted with a lower alkyl group, and R 4 and R 5 are combined with the adjacent nitrogen atom to form a piperidine ring. A compound according to claim 1. 3. The compound according to claim 1, wherein R and R 4 are hydrogen atoms, R 1 and R 3 are lower alkyl groups, R 2 is a cyclohexyl group substituted with a lower alkyl group, and R 5 is an acetyl group.
JP15809977A 1977-12-29 1977-12-29 Compound of aminophenyl ether and its preparation Granted JPS5492926A (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
JP15809977A JPS5492926A (en) 1977-12-29 1977-12-29 Compound of aminophenyl ether and its preparation
GB8124879A GB2086377B (en) 1977-12-29 1978-12-15 Cyclic aminophenyl ether compounds
GB7848658A GB2011888B (en) 1977-12-29 1978-12-15 Aminophenyl ether compoungd
CA318,098A CA1110248A (en) 1977-12-29 1978-12-18 Method of producing aminophenyl ether compound
DE19782854595 DE2854595A1 (en) 1977-12-29 1978-12-18 AMINOPHENYL ETHER COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND USE
FR7836263A FR2413382A1 (en) 1977-12-29 1978-12-22 AMINOPHENYL ETHER COMPOUNDS USED FOR THE TREATMENT OF ARTERIOSCLEROSIS
NL7812574A NL7812574A (en) 1977-12-29 1978-12-27 AMINOPHENYL ETHERS COMPOUNDS, METHODS FOR PREPARING THEM, AND PHARMACEUTICAL PREPARATIONS.
BE192584A BE873102A (en) 1977-12-29 1978-12-27 AMINOPHENYL ETHER COMPOUNDS USED FOR THE TREATMENT OF ARTERIOSCLEROSIS
DK584978A DK584978A (en) 1977-12-29 1978-12-28 METHOD OF MAKING AMINOPHENYLETHERE
SE7813355A SE7813355L (en) 1977-12-29 1978-12-28 AMINOPHENYLETHER ASSOCIATIONS
NO784394A NO784394L (en) 1977-12-29 1978-12-28 PROCEDURES FOR THE PREPARATION OF AMINOPHENYL ETHER COMPOUNDS
ES476458A ES476458A1 (en) 1977-12-29 1978-12-28 Aminophenyl Ether Compounds
IT7869973A IT7869973A0 (en) 1977-12-29 1978-12-28 AMINOPHENYL ETHERS PARTICULARLY USEFUL IN THERAPY AND PROCEDURE FOR THEIR PREPARATION
AU43017/78A AU4301778A (en) 1977-12-29 1978-12-29 Aminophenyl ether compounds
AT0935778A AT367738B (en) 1977-12-29 1978-12-29 METHOD FOR PRODUCING NEW AMINOPHENYL ETHER COMPOUNDS AND THEIR SALTS
ES481505A ES481505A1 (en) 1977-12-29 1979-06-12 Aminophenyl Ether Compounds
ES481504A ES481504A1 (en) 1977-12-29 1979-06-12 Aminophenyl Ether Compounds
CA356,441A CA1110246A (en) 1977-12-29 1980-07-17 Method of producing cyclic-aminophenyl ether compound
FR8016962A FR2457863A1 (en) 1977-12-29 1980-07-31 AMINOPHENYL ETHER COMPOUNDS FOR THE TREATMENT OF ARTERIOSCLEROSIS
NO820355A NO820355L (en) 1977-12-29 1982-02-05 PROCEDURES FOR THE PREPARATION OF CYCLIC AMINOPHENYL ETHER COMPOUNDS.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP15809977A JPS5492926A (en) 1977-12-29 1977-12-29 Compound of aminophenyl ether and its preparation

Publications (2)

Publication Number Publication Date
JPS5492926A JPS5492926A (en) 1979-07-23
JPS6129330B2 true JPS6129330B2 (en) 1986-07-05

Family

ID=15664272

Family Applications (1)

Application Number Title Priority Date Filing Date
JP15809977A Granted JPS5492926A (en) 1977-12-29 1977-12-29 Compound of aminophenyl ether and its preparation

Country Status (2)

Country Link
JP (1) JPS5492926A (en)
BE (1) BE873102A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ564759A (en) * 2005-06-30 2011-08-26 Prosidion Ltd GPCR agonists

Also Published As

Publication number Publication date
BE873102A (en) 1979-06-27
JPS5492926A (en) 1979-07-23

Similar Documents

Publication Publication Date Title
EP0178874B1 (en) Alkylsulfonamidophenylalkylamines
US5393768A (en) Leukotriene antagonists
US6660756B2 (en) N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
US4361562A (en) 3-Aminopropoxyaryl derivatives, their preparation and pharmaceutical compositions containing them
KR20010105394A (en) Diaryl Derivatives and Their Use as Medicaments
JPH05247028A (en) Novel 4-(4-imidazolyl)piperidine substituted at position 1, preparation thereof, and its therapeutic application
JPH075539B2 (en) Substituted sulfonamide benzamide and process for producing the same
NZ527012A (en) N-phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors for FSAD
JPH04507421A (en) 5-(1-aminocyclohexyl)-2(1H)-pyridinone and related compounds
FR2599739A1 (en) HYDROXAMIC BIPHENYL ACIDS WITH THERAPEUTIC ACTION
US4510156A (en) Bisindolyl alkylene ureas lipid absorption-inhibiting agents and their use thereas
WO1998045242A1 (en) Retinoid activity regulators
JP2005516898A (en) Piperazine derivatives having SST1 antagonist activity
JPS6314702B2 (en)
US4596827A (en) Alkylsulfonamidophenylalkylamine compounds used for treating arrhythmia
JPH02229168A (en) Pyrazolone derivative
US4578392A (en) Pyrazolo[1,5-a]pyridine derivatives and anti-allergic compositions containing them
JPS6129330B2 (en)
PL195667B1 (en) Novel cyclic compounds compounds comprising a cycloalkylene chain, method of obtaining them and pharmaceutic compositions containing such compounds
US3637827A (en) Benzhydryloxy-cyclopropanecarboxylic acids and amides
JPS63227570A (en) Isoquinoline derivative
JPS61115068A (en) 4-benzylpiperidinylpropoxyaniline derivative
NO784394L (en) PROCEDURES FOR THE PREPARATION OF AMINOPHENYL ETHER COMPOUNDS
US5141937A (en) 7-diphenylmethylenebicycloheptane or 7-diphenylmethylenebicylcoheptene derivatives
HU199792B (en) Process for producing new indolecarboxamide derivatives and pharmaceutical compositions comprising such compounds